AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03996694
Drug: Belbuca 300 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belbuca 300 µg buccal film
Trial: NCT03996694
Drug: Belbuca 600 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belbuca 600 µg buccal film
Trial: NCT03996694
Drug: Belbuca 900 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belbuca 900 µg buccal film
Trial: NCT03996694
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo buccal film and oral placebo
Trial: NCT01171794
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
Trial: NCT01171794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical number of visually identical tasteless pills as ibuprofen arm
Trial: NCT02379091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Namilumab placebo-matching subcutaneous injection
Trial: NCT02379091
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate tablets
Trial: NCT02379091
Drug: Folic/folinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic/folinic acid tablets
Trial: NCT00276341
Drug: EGb 761® (Tanakan®)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01511367
Drug: Flutiform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/5ug (fluticasone/formoterol) 2 puffs twice daily
Trial: NCT01673542
Drug: DEXERYL
RxNorm normalized name: Dexeryl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04120116
Drug: FX-322 (Two Doses)
RxNorm normalized name: Prevail-FX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive two doses of FX-322.
Trial: NCT04120116
Drug: FX-322 (Four Doses)
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive four doses of FX-322.
Trial: NCT04120116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Placebo.
Trial: NCT01724099
Drug: Euiiyin-tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Korean medicinal herbal drug
Trial: NCT01724099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug, same odor and formula as Euiiyin-tang
Trial: NCT01886053
Drug: Faropenem（low-dose group)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form: Injection dosage:2400 mg frequency: twice a day
Trial: NCT03523988
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen gel capsule
Trial: NCT03523988
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen gel capsule
Trial: NCT00665366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, once daily, 12 weeks
Trial: NCT00066157
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
Trial: NCT00066157
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal placebo patch, changed every 3 days, for 12 months
Trial: NCT00066157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet daily for 12 months
Trial: NCT00119184
Drug: spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spinal anesthesia
Trial: NCT00965458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
Trial: NCT01780974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules
Trial: NCT01580163
Drug: Traditional Chinese Medicine JITAI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet，Each tablet weight 0.4g
Trial: NCT00923572
Drug: EE30/DRSP (Yasmin, BAY86-5131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
Trial: NCT02716415
Drug: Destin Maximum Strength 40% Zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~* regular diaper changing,~* gentle cleansing~* application of the trial ointment
Trial: NCT00256997
Drug: Oral atypical Antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
Trial: NCT03863080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of Placebo
Trial: NCT00792467
Drug: ITF2357
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
Trial: NCT00991458
Drug: Placebo (Vehicle for Cyclosporine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Trial: NCT03471507
Drug: Bonipar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
Trial: NCT03471507
Drug: Diclofenac sodium topical solution 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
Trial: NCT00104286
Drug: Troxatyl™ (Cytotoxic Chemotherapeutic)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01699438
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets q.d. for 8 weeks
Trial: NCT02419001
Drug: Period 1 - Treatment Sequence AB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
Trial: NCT02419001
Drug: Period 1 - Treatment Sequence AC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
Trial: NCT00239330
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00433420
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00433420
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02393378
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate tablet
Trial: NCT02393378
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid Tablet
Trial: NCT00354978
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m\^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
Trial: NCT02426021
Drug: MLN1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of MLN1202
Trial: NCT02426021
Drug: MLN1202 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of MLN1202 placebo
Trial: NCT02887677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
Trial: NCT04130204
Drug: DYV700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprietary transdermal delivery platform
Trial: NCT00071890
Drug: Interleukin 2
RxNorm normalized name: Recombinant interleukin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
Trial: NCT00071890
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART from week 0 to week 24
Trial: NCT00071890
Drug: Treatment interruption
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART is interrupted from week 24 in both arms
Trial: NCT04130204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle transdermal delivery platform
Trial: NCT01955252
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).~Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.~Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.~For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months
Trial: NCT00545454
Drug: SSR150106
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00545454
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04248426
Drug: ATI-2173 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-2173 Placebo is used as an inactive comparator to ATI-2173. It will be dosed as a capsule by mouth.
Trial: NCT01949818
Drug: Yangzhengxiaoji capsule combined with CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
Trial: NCT01949818
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
Trial: NCT00750061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01403636
Drug: SAR245409
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule Route of administration: oral
Trial: NCT03417245
Drug: factor concentrates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: by intravenous (IV) injection
Trial: NCT03337477
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).
Trial: NCT03181932
Drug: Placebo inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 participants are to be treated with double-blind placebo (75 subjects ≤21 years old, 25 subjects \>21 years old) for 24 weeks during Period 1.
Trial: NCT00744497
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01744262
Drug: Total intravenous anesthesia
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5\~4 µg/mL and remifentanil effect site concentration 2\~5 ng/mL.
Trial: NCT01744262
Drug: Inhalation Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction with intravenous propofol bolus of 1.5\~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5\~2.0 % and remifentanil effect site concentration 2\~5 ng/mL.
Trial: NCT02183649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02035891
Drug: placebo 0.5mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
Trial: NCT01110902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00370968
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03694886
Drug: Caffeine Anhydrous with small sucrose pill
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule
Trial: NCT03694886
Drug: Caffeine Anhydrous with large sucrose pill
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule
Trial: NCT00431106
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
Trial: NCT00457951
Drug: ODSH
RxNorm normalized name: Octasulfated Disaccharide Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized, Blinded, ODSH Arm
Trial: NCT03868657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01193244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of \<50 ng/dL.
Trial: NCT05361005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT01462370
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg tablet given orally for one dose.
Trial: NCT01462370
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.
Trial: NCT01462370
Drug: Placebo to etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to etoricoxib, one tablet.
Trial: NCT01462370
Drug: Placebo to ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to ibuprofen, up to four 3-capsule doses.
Trial: NCT01462370
Drug: Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.
Trial: NCT04435431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use
Trial: NCT00003526
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT03877510
Drug: IPX203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX203 extended release capsules
Trial: NCT01038843
Drug: VA106483
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above
Trial: NCT01747876
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEE011 is a small molecule inhibitor of CDK4/6.
Trial: NCT00912431
Drug: ABT-126
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-126 administered on Day 1 of Period 1
Trial: NCT00912431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for ABT-126 administered on Day 1 of Period 2
Trial: NCT00988806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment.
Trial: NCT03023358
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750mg/m2 iv on day 1
Trial: NCT03023358
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/m2 iv on day 1
Trial: NCT00740649
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02870907
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m²/d, IV from D22 to D26.
Trial: NCT02870907
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m²/d, IV from D22 à D24.
Trial: NCT04617626
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of azithromycin suspension
Trial: NCT02802540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients going to take capsules of placebo until complete 8 weeks.
Trial: NCT00815659
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
Trial: NCT00639223
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 20mg capsule twice daily for 12 weeks
Trial: NCT03894683
Drug: Melatonin 10 mg
RxNorm normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin tablets (10 mg)
Trial: NCT03894683
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets manufactured the same as melatonin tablets
Trial: NCT03071926
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg, qw, first 6 weeks ,every 8 weeks
Trial: NCT03290131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00576433
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As prescribed
Trial: NCT03920813
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.
Trial: NCT02200406
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.